Biostem Technologies Inc (BSEM) Stock Price, Quote & News

Company Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of...

Industry: Biotechnology

Sector: Healthcare

Phone: 954 380 8342

Website: biostemtechnologies.com

Address:

4901 Northwest 17th Way, Suite 606, Fort Lauderdale, United States

GlobalInsights Aug. 13 at 1:47 PM

$BSEM Now that BSEM is on the NASDAQ the quant trading algorithms will determine where the shares trade. No humans involved

0 · Reply

GlobalInsights Aug. 13 at 1:44 PM

$BSEM Well Rabbi guess I should have said something negative to help prevent investors in believing in the shady characters running this company. Guess Nasdaq up listing isn’t all it’s cracked up to be.

0 · Reply

StocktwitsEarnings Aug. 12 at 10:08 PM

$BSEM Q2 '26 Earnings Results & Recap BioStem Technologies reported Q2 2026 net revenue of $7.9M, a 28% YoY decrease, driven by CMS reimbursement changes that reduced physician office revenue by 90% compared to Q2 2025.

0 · Reply

ajmrtxl Aug. 12 at 4:18 PM

$BSEM 's latest squeeze play

0 · Reply

GlobalInsights Aug. 12 at 4:07 AM

$BSEM Earnings release and 10Q should be interesting to see how the business is operating now that they are play by the rules everyone else is. Also, the 10Q will offer investors a lot more information than they reported as a pink sheet company.

0 · Reply

ContrarianCraft Aug. 7 at 4:55 PM

I honestly dont understand the valuation gap between these two RMTG has a better balance sheet better margins better growth and better profits $BSEM is trailing in every category but still trades at a premium it seems like the market hasnt looked at the actual numbers for RMTG yet

0 · Reply

MomentumMaker Aug. 7 at 4:53 PM

The share price of RMTG is under ten cents but the revenue they are producing is multiple times their market cap that sort of mispricing usually corrects itself over time when the market wakes up $BSEM is priced for perfection despite being deep in the red and that is a much riskier setup

0 · Reply

QuantQuantum Aug. 7 at 4:52 PM

RMTG is profitable right now and growing fast thats a rare combo in the microcap world $BSEM is losing money and shrinking in terms of operating performance if you compare the bottom line of both companies its not even close RMTG is winning on every financial metric

0 · Reply

ShortShifter Aug. 7 at 4:51 PM

What really stands out to me is the equity position of both companies RMTG has positive shareholders equity which means they have a buffer against any downturns $BSEM has a deficit which means they are technically insolvent on paper that is a massive differance in risk profile for anyone looking at the balance sheets

0 · Reply

ForexFlow Aug. 7 at 4:50 PM

The peptide and stem cell industry is booming right now and RMTG is capitalizing on that growth with real revenue and real earnings $BSEM is present in the sector but they arent converting that market opportunity into profits yet the difference in execution is obvious when you compare the quarterly filings

0 · Reply

BioStem Technologies Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 20 hours ago

BioStem Technologies Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 20 hours ago

BioStem Technologies Earnings release: Q2 2026

Aug 12, 2026, 4:05 PM EDT - 21 hours ago

BioStem Technologies Reports Second Quarter 2026 Financial Results

2026-07-10T11:05:27.000Z - 4 weeks ago

BioStem files registration statement with SEC, to pursue Nasdaq listing

2026-07-08T12:15:41.000Z - 5 weeks ago

BioStem Technologies issued four U.S. design patents for allograft technology

Jul 8, 2026, 8:00 AM EDT - 5 weeks ago

BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies

2026-05-20T13:06:23.000Z - 3 months ago

BioStem Technologies announces notice of allowance for four patents

2026-05-15T17:08:54.000Z - 3 months ago

BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright

2026-05-07T03:26:41.000Z - 3 months ago

Biostem Technologies initiated with a Buy at H.C. Wainwright

Mar 23, 2026, 11:40 AM EDT - 5 months ago

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair

Jan 21, 2026, 6:00 PM EST - 7 months ago

BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies

Jan 10, 2026, 7:00 AM EST - 7 months ago

BioStem Technologies Slides: Conference presentation

Oct 27, 2025, 4:15 PM EDT - 10 months ago

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant

Mar 31, 2025, 7:00 AM EDT - 1 year ago

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Jan 8, 2025, 7:00 AM EST - 1 year ago

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Jan 2, 2025, 7:00 AM EST - 1 year ago

BioStem Technologies CEO to Present at Biotech Showcase 2025

Oct 23, 2024, 7:00 AM EDT - 1 year ago

BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT

Aug 29, 2024, 7:00 AM EDT - 2 years ago

BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

Jul 16, 2024, 8:12 AM EDT - 2 years ago

BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments

Jun 17, 2024, 2:07 PM EDT - 2 years ago

UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion

Jun 17, 2024, 10:17 AM EDT - 2 years ago

PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion

Apr 30, 2024, 8:30 AM EDT - 2 years ago

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

Dec 14, 2023, 8:30 AM EST - 2 years ago

Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions

Sep 14, 2023, 8:00 AM EDT - 3 years ago

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

Sep 11, 2023, 8:00 AM EDT - 3 years ago

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

Sep 6, 2023, 12:00 PM EDT - 3 years ago

BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell

Mar 23, 2023, 7:30 AM EDT - 3 years ago

BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products

Mar 7, 2023, 7:30 AM EST - 3 years ago

BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.

Feb 14, 2023, 8:55 AM EST - 3 years ago

BioStem Technologies Enters Into a Share Exchange Agreement

Feb 1, 2023, 7:30 AM EST - 3 years ago

BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing

Jan 24, 2023, 7:30 AM EST - 3 years ago

Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions

Dec 16, 2022, 7:30 AM EST - 3 years ago

BioStem Technologies Announces Up-Listing to the OTCQB Venture Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

BioStem Technologies Announces Partnership with Kill Cliff FC

Nov 15, 2022, 4:05 PM EST - 4 years ago

BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results

Nov 15, 2022, 7:30 AM EST - 4 years ago

BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call

Oct 26, 2022, 7:30 AM EDT - 4 years ago

BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer

Oct 10, 2022, 7:30 AM EDT - 4 years ago

BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Sep 13, 2022, 7:30 AM EDT - 4 years ago

BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts

Sep 8, 2022, 7:30 AM EDT - 4 years ago

BioStem Technologies Strengthens its Board of Directors and Audit Committee with the Appointment of Accomplished Medtech Financial Leader Brandon Poe

Aug 22, 2022, 4:01 PM EDT - 4 years ago

BioStem Technologies Reports Second Quarter 2022 Operating and Financial Results

Aug 16, 2022, 7:30 AM EDT - 4 years ago

BioStem Technologies to Host Second Quarter Financial Results and Corporate Update Conference Call on August 22nd

Jun 17, 2022, 9:25 AM EDT - 4 years ago

BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022

May 16, 2022, 12:25 PM EDT - 4 years ago

BioStem Technologies Reports March 31, 2022 Record Quarterly Financial Results

Apr 1, 2022, 10:00 AM EDT - 4 years ago

BioStem Technologies Inc. Reports December 31, 2021 Year End Financial Results

Nov 1, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®

Aug 25, 2021, 11:15 AM EDT - 5 years ago

BioStem Technologies Reports Record Breaking Second Quarter Sales

Jul 27, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.

Jul 23, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Awarded Q Code for VENDAJE® Product Line From CMS.

May 24, 2021, 11:34 AM EDT - 5 years ago

BioStem Technologies Announces Filing of 2021 First Quarter Financial Reports

Apr 20, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc., Announces the Addition of Three Key Scientific Advisory Board Members

Apr 15, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Announces Launch of National Sales Force Expansion

Apr 5, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Reports Financial Results for Fourth Quarter and Fiscal Year 2020

Mar 25, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™

Mar 15, 2021, 9:00 AM EDT - 5 years ago

BioStem Technologies Engages D. Brooks & Associates for 2020 and 2019 Audit

Dec 24, 2020, 2:00 PM EST - 6 years ago

BioStem Technologies, Announces Filing of 2020 Quarterly Reports

GlobalInsights Aug. 13 at 1:47 PM

$BSEM Now that BSEM is on the NASDAQ the quant trading algorithms will determine where the shares trade. No humans involved

0 · Reply

GlobalInsights Aug. 13 at 1:44 PM

0 · Reply

StocktwitsEarnings Aug. 12 at 10:08 PM

0 · Reply

ajmrtxl Aug. 12 at 4:18 PM

$BSEM 's latest squeeze play

0 · Reply

GlobalInsights Aug. 12 at 4:07 AM

0 · Reply

ContrarianCraft Aug. 7 at 4:55 PM

0 · Reply

MomentumMaker Aug. 7 at 4:53 PM

0 · Reply

QuantQuantum Aug. 7 at 4:52 PM

0 · Reply

ShortShifter Aug. 7 at 4:51 PM

0 · Reply

ForexFlow Aug. 7 at 4:50 PM

0 · Reply

OptionsOwner Aug. 7 at 4:49 PM

$BSEM has a lot of hype around it but the financial statements tell a different story they are losing money and diluting shareholders to stay alive RMTG is quietly building a profitable business with a tiny market cap and no dilution the fundamentals favor RMTG in almost every category

0 · Reply

ScalpSense Aug. 7 at 4:48 PM

The management team at RMTG seems to be running a very lean operation they are growing sales without ballooning their SG&A expenses which is exactly what you want to see $BSEM on the other hand is spending too much on admin and marketing without seeing corresponding revenue growth that inefficiency is killing their bottom line

0 · Reply

BookValueBoss Aug. 7 at 4:47 PM

I ran the numbers on both companies and the price to sales ratio for RMTG is incredibly low compared to $BSEM if RMTG traded at the same multiple as BSEM their share price would be significantly higher its just basic arithmetic based on the revenues they are reporting and the revenue gap is widening every quarter

0 · Reply

IncomeInventor Aug. 7 at 4:44 PM

If you take the current market cap of RMTG and look at their Q1 revenue its actually smaller than their quarterly sales that is an insane baseline for valuation now look at $BSEM their market cap is massive compared to their revenue and their growth is lagging far behind the numbers just dont add up for BSEM the way they do for RMTG

0 · Reply

GlobalGainer Aug. 7 at 4:42 PM

When you strip away all the hype and just look at the hard numbers RMTG is the stronger play on paper they have positive equity they have growing revenue and they have net income $BSEM has high debt loads negative equity and recurring losses the fundamentals just arent comparable

0 · Reply

MacroMastery Aug. 7 at 4:41 PM

Ive been following the stem cell and peptide sector for a while and its clear that RMTG is one of the few microcaps actually hitting their targets they are growing rapidly and they are doing it with a clean balance sheet $BSEM is hanging on by a thread with debt and dilution and their growth rate is nowhere near what RMTG is showing

0 · Reply

LongTermLeader Aug. 7 at 4:40 PM

The first quarter results really highlight the difference between the two RMTG showed rapid revenue growth and a profitable bottom line $BSEM posted another quarter of red ink and stagnant sales if you compare the income statements directly one company is executing and the other is just hoping for a turnaround

0 · Reply

AnalystAdvisor Aug. 7 at 4:38 PM

RMTG is under ten cents and yet they are generating revenue thats bigger than their entire market cap that is a valuation metric that you just dont see in the biotech space very often $BSEM on the flip side has a huge market cap but their sales numbers are tiny compared to their valuation and they arent even growing the top line like RMTG is

0 · Reply

MoatBuilder Aug. 7 at 4:37 PM

If you look at the share structures side by side its pretty alarming $BSEM has a history of diluting shares to stay afloat which hurts everyone holding the stock RMTG has a stable float and they arent reliant on secondary offerings because their business is already self funding that is a huge advantage for RMTG holders going forward

0 · Reply

DividendDealer Aug. 7 at 4:36 PM

The peptide market is exploding and both companies are in the space but only one is actually making money RMTG is selling treatments and banking profits while $BSEM is spending way too much on overhead and not getting the return on that investment when the market realizes which one is actually profitable the valuation gap is going to shrink dramatically

0 · Reply

EarningsExploit Aug. 7 at 4:34 PM

The valuation multiples are completely out of whack when you compare these two $BSEM trades at many times sales because people are betting on the future but RMTG is already delivering that future today they have net income they have growing revenue and they have a share price that is literally pennies if you applied BSEM current price to sales ratio to RMTG the stock would be sitting at over a dollar easily

0 · Reply

SupportStrong Aug. 7 at 4:33 PM

Let’s talk about the balance sheet because thats where the real story is RMTG has positive equity and a clean debt profile they can fund their own growth without begging for dilution $BSEM is sitting on negative equity and has to constantly issue new shares just to keep the lights on that is a massive differance in financial health and it shows in their quarterly filings

0 · Reply

Market Cap	104.94M
Revenue (ttm)	0.00
Net Income (ttm)	0.00
EPS (ttm)	N/A
PE Ratio	7.91
Forward PE	23.17
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	90,000
Avg Vol	119,018
Day's Range	N/A - N/A
Shares Out	16.82M
Stochastic %K	50%
Beta	-0.38
Analysts	Strong Buy
Price Target	$25.50